Evaluate the Effect of Aclidinium Bromide on Long-term Cardiovascular Safety and Exacerbations in Moderate to Very Severe COPD Patients.

NCT01966107 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

3635

Enrollment

INDUSTRY

Sponsor class

Conditions

COPD
Chronic Obstructive Pulmonary Disease
Moderate to Very Severe COPD

Interventions

DRUG: Aclidinium Bromide
DRUG: Placebo

Sponsor

AstraZeneca